Home | Register | Login | Inquiries | Alerts | Sitemap |  


Advanced Search
JKM > Volume 37(3); 2016 > Article
Lee, Kim, Kim, and Kim: A review of traditional Korean medical treatment for cancer-related cognitive impairment

Abstract

Objectives

This article aims to review clinical studies related to traditional Korean medicine (TKM) for cancer-related cognitive impairment (CRCI) up to date.

Methods

EMBASE, Pubmed and eight Korean databases were searched for clinical studies about TKM for CRCI up to July 2016. We selected articles about subjects with cancer, using TKM interventions including acupuncture, moxibustion or herbal medicine, containing assessment about cognitive function.

Results

Two randomized controlled trials (RCTs) and one randomized controlled feasibility study were included. Selected studies were containing assessments about cognitive function but not as primary outcomes. The three studies included one acupuncture study and two herbal-medicine studies. Only one herbal-medicine study showed improvement in cognitive function.

Conclusions

Few clinical studies mainly focusing CRCI treated with TKM have been performed and have shown contradictory results until now. Future studies should be performed considering findings from pre-clinical and clinical studies altogether, and they should be controlled to minimize risk of bias thorough out overall courses of designing, conducting and reporting them.

Fig. 1
Study flow diagram about traditional Korean medicine for cancer-related cognitive impairment
KM, Korean medicine; EA, electroacupuncture; CRCI, cancer-related cognitive impairment; RCT, randomized controlled trial
jkm-37-3-74f1.gif
Fig. 2
Risk of bias graph about traditional Korean medicine for cancer-related cognitive impairment
jkm-37-3-74f2.gif
Fig. 3
Risk of bias summary about traditional Korean medicine for cancer-related cognitive impairment
jkm-37-3-74f3.gif
Table 1
Characteristics of Included Studies (n=3)
Study ID Subjects; N (TG: CG); mean age (TG:CG); Intervention (sessions, duration) Assessment for cognitive function (time point) Result
ATX
Johnston 201135) Breast cancer survivors, Female, 18–65yrs old, BFI ≥4, Finished primary cancer therapy; N= 5:7; Mean age= 55.0:53.0yrs old; TG: usual care + Education with ATX
(50 min*8 sessions ATX; 50 min *4 sessions education; for 8 wks)
CG: usual care only (8 wks)
FACT-COGv2
(Prior to beginning of Tx and after Tx ends. Up to an average of 44 wks)
  1. BFI: NS but clinically meaningful with ES 1.85

  2. FACT-COGv2: NS

HM
Chan 201134) Ovarian cancer, Female, ≥18yrs old, who need chemotherapy; N= 31:28; Mean age=52.9:51.5 yrs old; TG: standard CT + TCM herb powder CG: standard CT + placebo
(b.i.d., for 1st – 6th cycles of CT)
EORTC-cognition
(3rd cycle of CT and 4 wks after the 6th cycle)
  1. EORTC-QLQ-C30: NS between groups, both improved

  2. EORTC-cognition:

    • After 3 cycles: Worse in TG (−9.14±5.12) than CG (7.1±4.81). The change was significantly different*

    • After 6 cycles: NS in either group

  3. Immune function: total lymphocyte count maintained in TG only

Sun 201533) Stage IV Gastric cancer, Either sex, 18–90yrs old, KPS>30, expected survival >3mos; N=19:20; Mean age=NR; TG: CHD + Jinlongshe Granule
CG: CHD + placebo
(t.i.d., for ≥ 3 mos)
EORTC-cognition
(3, 6, 9, 12 and 15 mos after Tx)
  1. EORTC-QLQ-C30: generally improved in TG** except dyspnea, diarrhea

  2. EORTC-cognition: improved in TG with F=7.103 (p=0.001)**

BFI, brief fatigue inventory; ATX, acupuncture; TG, treatment group; CG, control group; FACT-COGv2, functional assessment of cancer treatment cognitive scale V2; NS, not significant; ES, effect size; HM, herbal medicine; TCM, traditional Chinese medicine; CT, chemotherapy; b.i.d., twice a day; CHD, Chinese herbal decoctions; t.i.d., three-times a day; KPS, Karnofsky performance score; NR, not reported; Tx, treatment; EORTC-cognition, EORTC-QLQ-C30 cognitive function subscale;

* , statistically significant (p<0.05);

** , statistically significant (p<0.01);

† CT, 3 weekly;

참고문헌

1 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, et al. Survivorship: cognitive function, version 1.2014. Journal of the National Comprehensive Cancer Network : JNCCN. 2014; 12:7. 976–86.


2 Cheung YT, Chui WK, Chan A. Neurocognitive impairment in breast cancer patients: pharmacological considerations. Critical reviews in oncology/hematology. 2012; 83:1. 99–111.
crossref

3 Park JH, Bae SH, Jung YS, Jung YM. Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer. J Korean Acad Nurs. 2015; 45:1. 118–28.
crossref

4 Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016; 34:6. 611–35.
crossref

5 Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncology. 2011; 12:7. 703–8.
crossref

6 Kohli S, Griggs JJ, Roscoe JA, Jean-Pierre P, Bole C, Mustian KM, et al. Self-reported cognitive impairment in patients with cancer. Journal of oncology practice/American Society of Clinical Oncology. 2007; 3:2. 54–9.
crossref

7 Ahles TA, Correa DD. Neuropsychological impact of cancer and cancer treatments. Psycho-oncology. 2010; 251–7.
crossref

8 Palmer JL, Trotter T, Joy AA, Carlson LE. Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. Journal of cancer survivorship : research and practice. 2008; 2:4. 275–82.
crossref

9 Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010; 28:8. 1294–300.
crossref

10 Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast cancer research and treatment. 2008; 110:1. 143–52.
crossref

11 Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2011; 19:10. 1647–56.
crossref

12 Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. International review of psychiatry (Abingdon, England). 2014; 26:1. 102–13.
crossref

13 Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Current neurology and neuroscience reports. 2012; 12:3. 267–75.
crossref

14 Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. Journal of Clinical Oncology. 2007; 25:17. 2455–63.
crossref

15 Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer journal (Sudbury, Mass). 2008; 14:6. 396–400.
crossref

16 Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Journal of Clinical Oncology. 2012; 30:10. 1080–6.
crossref

17 de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Human brain mapping. 2012; 33:12. 2971–83.
crossref

18 Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Human brain mapping. 2011; 32:3. 480–93.
crossref

19 Kesler SR, Watson C, Koovakkattu D, Lee C, O’Hara R, Mahaffey ML, et al. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain imaging and behavior. 2013; 7:4. 501–10.
crossref

20 Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012; 20:4. 831–9.
crossref

21 Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nature reviews. Cancer. 2007; 7:3. 192–201.


22 Raffa RB. A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’). Journal of clinical pharmacy and therapeutics. 2011; 36:3. 257–9.
crossref

23 Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA: a cancer journal for clinicians. 2015; 65:2. 123–38.
crossref

24 Ju C. Hwang Jae Nae Kyeong Yeongchu. Cheonghong;2007.


25 Committee for the textbook of Traditional Korean neuropsychiatry. Traditonal Korean medical Neuropsychiatry. 1:Jipmoon;2007.


26 Committee for the textbook of the acupuncture and moxibustion. Amnesia and Dementia. The acupuncture and moxibustion 3. 2:Jipmoon;2008.


27 Lee BH, Kim HY, Park JH, Yang TY, Jang EY, Jeon HS, et al. Effect of acupuncture on the short term memory. The journal of East-West medicine. 2015; 40:3. 13–23.


28 Yun J, Kim Y, Lee C. A prison without bars: defect-punctured cancer-survivors management. Segye newspaper. 2016. Available at: URL: http://www.segye.com/content/html/2016/07/06/20160706003541.htmlAccessed July 6, 2016.


29 Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. Journal of cancer survivorship : research and practice. 2009; 3:4. 223–32.
crossref

30 Towler P, Molassiotis A, Brearley S. What is the evidence for the use of acupuncture as an intervention for symptom management in cancer supportive and palliative care: an integrative overview of reviews. Supportive Care in Cancer. 2013; 21:10. 2913–23.
crossref

31 Liu F, Li ZM, Jiang YJ, Chen LD. A meta-analysis of acupuncture use in the treatment of cognitive impairment after stroke. Journal of alternative and complementary medicine (New York, NY). 2014; 20:7. 535–44.
crossref

32 Cao H, Wang Y, Chang D, Zhou L, Liu J. Acupuncture for vascular mild cognitive impairment: a systematic review of randomised controlled trials. Acupuncture in medicine : journal of the British Medical Acupuncture Society. 2013; 31:4. 368–74.
crossref

33 Sun DZJ, Zhang JP, Xu X, Ye JY, Xiu M, Zhao LJ, et al. Therapeutic effect of Jinlongshe Granule () on quality of life of stage IV gastric cancer patients using EORTC QLQ-C30: A double-blind placebo-controlled clinical trial. Chinese journal of integrative medicine. 2015; 21:8. 579–86.
crossref

34 Chan KKY, Jones TJ, Zhao B, Ma JF, Leung FK, Lau CY, et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011; 22:10. 2241–9.
crossref

35 Johnston MFH, Subramanian RD, Elashoff SK, Axe RM, Li EK, Kim JJ, et al. Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study. BMC complementary and alternative medicine. 2011; 11:49
crossref

36 Yun YH, Park YS, Lee ES, Bang SM, Heo D, Park S, et al. Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research. 2004; 13:4. 863–8.
crossref

37 Deng M, Wang XF. Acupuncture for amnestic mild cognitive impairment: a meta-analysis of randomised controlled trials. Acupuncture in Medicine. 2016; acupmed-2015-010989.
crossref

38 Hwang D. Bang-Yak-Hap-Pyun(方藥合編). Younglim. 2010.


39 LI Cj, WEI Pk, YU Bl. Study on the mechanism of Xiaotan Sanjie Recipe for inhibiting proliferation of gastric cancer cells. Journal of Traditional Chinese Medicine. 2010; 30:4. 249–53.
crossref

40 Joo SK, Kim GW, Goo BS, Kim CH. Effects of Arisaematics rhizoma on Ischemic Damage and Cytotoxicity in Brain. Journal of Korean Medicine. 2001; 2:1.


41 Won HY, Choi CW, Kim KS, Kim KO, Lee DW, Kim SY. The effects of Banhabaekchulchunma-Tang (BCT) on Dementia induced by focal brain ischemic injury in rats. Journal of Oriental Neuropsychiatry. 2006; 17:2. 61–73.


42 Kim S, Ryu B, Ryu K, Park D. Study of (386) 대한한의학회지 제 37 권 제 3 호 (2016 년 9 월) anti-cancer effects of Cremastrae Appendiculatae Tuber on stomach cancer cells. J Korean Oriental Med. 2001; 22:2. 75–83.


43 Seo B, Lee E. A Philological Study on poisoning of Pseudobulbus Cremastrae Appendiculatae. Journal of applied oriental medicine. 2003; 3:1. 73–82.


44 Kim H, Hong S. The anti-inflammatory effects of Huang-Lyun (Coptidis Rhizoma, CR) on injured tissue after burn elicitation. J Korean Oriental Med. 2011; 32:2. 1–13.


45 Jeong MY, Kim YH, Lee NK, Lee JY, Herr Y, Lee JH, et al. Antimicrobial effect on the periodontal pathogens and anti-inflammatory effect of Eriobotryae Folium. J Korean Orient Med. 2008; 29:182–92.


46 Avisar AR, Schiff Y, Bar-Sela E, Steiner G, Ben-Arye M. Chemotherapy-related cognitive impairment: does integrating complementary medicine have something to add? Review of the literature. Breast cancer research and treatment. 2012; 136:1. 1–7.
crossref

47 Johnston MFY, Hui C, Xiao KK, Li B, Rusiewicz X. Acupuncture for chemotherapy -associated cognitive dysfunction: a hypothesis -generating literature review to inform clinical advice. Integrative cancer therapies. 2007; 6:1. 36–41.
crossref

48 Yu SJ, Tseng J, Fu Ling. a Chinese herbal drug, modulates cytokine secretion by human peripheral blood monocytes. International journal of immunopharmacology. 1996; 18:1. 37–44.
crossref

49 Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. The Journal of neuroscience. 2006; 26:42. 10709–16.
crossref

50 O’Sullivan E, Higginson I. Clinical effectiveness and safety of acupuncture in the treatment of irradiation-induced xerostomia in patients with head and neck cancer: a systematic review. Acupuncture in Medicine. 2010; 28:4. 191–9.
crossref

51 Sun X, Zhang X, Nian JY, Guo J, Yin Y, Zhang GL, et al. Chinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta -Analysis. Evidence-based complementary and alternative medicine : eCAM. 2016; 2016:3281968
crossref

Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-2658-3627   Fax : +82-2-2658-3631   E-mail : skom1953@daum.net
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
powerd by m2community